BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax™ Phase I/IIa Clinical Trial

October 8, 2015

Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site.
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase I/IIa study of BriaVax™.
BriaCell has submitted to the US Food and Drug Administration (FDA) final positive results its first lot of BriaVax™ which is to be used in BriaCell’s upcoming Phase I/IIa clinical trial. These data were specifically requested by the FDA prior to initiating the BriaVax™ trial. Importantly, the data demonstrate that the first lot of BriaVax™ meets all purity, identity, potency and safety requirements for use in patients. The FDA is allowed thirty days to review and respond to the Company’s submission.

Read More
Skip to content